Absci

Absci Earnings Yield

The Earnings Yield of Absci (ABSI) as of Oct 16, 2026 is -30.04 %. In the previous year, Earnings Yield was -26.89 % — a change of 11.71% (lower).

Earnings Yield

-30.04 %

YoY

11.71%

Last updated:

Earnings Yield of Absci is 2025 -30.04 % . Earnings Yield of Absci was 2024 -26.89 % . It decreases by 11.71% lower compared to the previous year.

The Absci Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2019
-1.72 USD
Jan 1, 2020
-3.74 USD
Jan 1, 2021
-26.33 USD
Jan 1, 2022
-27.36 USD
Jan 1, 2023
-28.83 USD
Jan 1, 2024
-26.89 USD
Jan 1, 2025
-30.04 USD
The Absci Earnings Yield history
YEAREarnings YieldYoY
-30.04 %+11.71%
-26.89 %-6.75%
-28.83 %+5.40%
-27.36 %+3.91%
-26.33 %+603.41%
-3.74 %+118.00%
-1.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Absci Stock analysis

What does Absci do? Absci Corp, trading under the ticker ABSI with ISIN US00091E1091, is a biotechnology company headquartered in Vancouver, Washington, operating within the Health Care sector. The company went public via an IPO on July 22, 2021. Absci employs 140 people. It leverages artificial intelligence and synthetic biology to explore and expand the therapeutic potential of proteins. The company utilizes a platform combining AI with scalable wet lab technologies to develop biologics for patients. Absci's approach involves identifying novel drug targets, discovering biotherapeutic candidates, and generating cell lines for manufacturing within a single integrated process. The firm applies generative AI to design drug candidates optimized for target affinity, safety, manufacturability, and other characteristics. Absci's technology includes SoluPro, a multiplex synthetic biology method that addresses limitations of high-throughput automation labs. The company supports its AI-driven designs with high-throughput functional validation capabilities in its wet lab. Absci's website is www.absci.com, providing information about its services and technology. The company focuses on creating biologic drug candidates for partners, using data generated from its processes to refine and improve its platform. Absci is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Absci stock

Earnings Yield of Absci is -30.04 % in 2025.

Earnings Yield of Absci changed from -26.89 % to -30.04 %, representing a 11.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Absci since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Absci with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Absci

All Key Metrics — Absci